Inogen, Inc. (INGN) Bundle
Understanding Inogen, Inc. (INGN) Revenue Streams
Understanding Inogen, Inc.’s Revenue Streams
The financial health of Inogen, Inc. is significantly reflected in its revenue streams, which consist of various categories including product sales and rental income. This section will analyze these revenue sources, year-over-year growth, and the contributions from different business segments.
Breakdown of Primary Revenue Sources
| Revenue Category | 2024 (in thousands) | 2023 (in thousands) | Change ($) | Percentage Change (%) | Percentage of Total Revenue 2024 (%) | Percentage of Total Revenue 2023 (%) |
|---|---|---|---|---|---|---|
| Sales Revenue | $212,449 | $192,203 | $20,246 | 10.5% | 83.1% | 80.2% |
| Rental Revenue | $43,175 | $47,561 | $(4,386) | -9.2% | 16.9% | 19.8% |
| Total Revenue | $255,624 | $239,764 | $15,860 | 6.6% | 100.0% | 100.0% |
Year-over-Year Revenue Growth Rate
The total revenue for the nine months ended September 30, 2024, reached $255.6 million, which represents a 6.6% increase compared to $239.8 million for the same period in 2023. The growth in sales revenue was primarily driven by increased demand in both domestic and international business-to-business sales.
Contribution of Different Business Segments
Revenue contributions from different segments for the nine months ended September 30, 2024 are detailed below:
| Segment | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Change ($) | Percentage Change (%) |
|---|---|---|---|---|
| Business-to-Business Domestic Sales | $61,158 | $48,145 | $13,013 | 27.0% |
| Business-to-Business International Sales | $88,894 | $67,877 | $21,017 | 31.0% |
| Direct-to-Consumer Domestic Sales | $62,397 | $76,181 | $(13,784) | -18.1% |
| Direct-to-Consumer Domestic Rentals | $43,175 | $47,561 | $(4,386) | -9.2% |
Analysis of Significant Changes in Revenue Streams
The analysis reveals notable shifts in revenue streams. Sales revenue increased by 10.5% largely due to higher business-to-business sales, with approximately 119,100 oxygen systems sold in the nine months ended September 30, 2024, compared to 96,400 systems in the prior year, marking a 23.5% increase. Conversely, rental revenue declined by 9.2%, influenced by a shift towards lower private-payor reimbursement rates.
Overall, the revenue analysis indicates a robust growth trajectory in sales revenue, while rental revenue faces challenges that require strategic adjustments to optimize profitability.
A Deep Dive into Inogen, Inc. (INGN) Profitability
Profitability Metrics
Gross Profit Margin: For the nine months ended September 30, 2024, the total gross profit was $118,452 thousand compared to $98,541 thousand for the same period in 2023, representing a growth of 20.2% year-over-year. The gross margin percentage for sales revenue was 46.7% in 2024 versus 38.2% in 2023, while the gross margin percentage for rental revenue decreased to 44.4% from 52.6% during the same period.
Operating Profit: The operating loss for the nine months ended September 30, 2024, was $(31,130) thousand compared to $(80,404) thousand for the same period in 2023. This represents a significant reduction in operating loss, demonstrating improved operational efficiency.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $(26,131) thousand, a decrease from $(75,894) thousand in the same period in 2023, marking a 65.6% improvement. The net loss per share attributable to common stockholders for 2024 was $(0.25) compared to $(1.97) in 2023.
| Metric | 2024 (9 Months) | 2023 (9 Months) | Change ($ Thousand) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $255,624 | $239,764 | $15,860 | 6.6% |
| Gross Profit | $118,452 | $98,541 | $19,911 | 20.2% |
| Operating Loss | $(31,130) | $(80,404) | $49,274 | 61.2% |
| Net Loss | $(26,131) | $(75,894) | $49,763 | 65.6% |
Trends in Profitability: The profitability metrics indicate a clear trend of improving financial health, with gross profit margins increasing significantly due to better cost management and a favorable sales mix. The reduction in net loss showcases effective operational adjustments.
Comparison with Industry Averages: As of 2024, the gross margin for the company at 46.3% is above the industry average of approximately 40%, indicating strong competitive positioning.
Operational Efficiency: Cost of sales revenue decreased by $5,544 thousand for the nine months ended September 30, 2024, primarily due to reduced material cost premiums, which improved the overall gross margin.
Debt vs. Equity: How Inogen, Inc. (INGN) Finances Its Growth
Debt vs. Equity: How Inogen, Inc. Finances Its Growth
As of September 30, 2024, Inogen, Inc. reported total liabilities of $120.8 million. This includes both current and long-term components, reflecting the company's overall debt levels.
Overview of the Company's Debt Levels
Inogen's current liabilities stood at $72.4 million, while long-term liabilities totaled $48.4 million. The breakdown of current liabilities includes:
- Accounts payable and accrued expenses: $27.0 million
- Accrued payroll: $14.3 million
- Warranty reserve - current: $9.5 million
- Operating lease liability - current: $2.8 million
- Earnout liability: $11.8 million
- Deferred revenue - current: $7.0 million
Debt-to-Equity Ratio
The debt-to-equity ratio is a crucial metric for assessing financial leverage. As of September 30, 2024, Inogen's total stockholders' equity was $185.4 million. This results in a debt-to-equity ratio of approximately:
Debt-to-Equity Ratio = Total Debt / Total Equity = $120.8 million / $185.4 million ≈ 0.65
This ratio is below the industry average of around 1.0, indicating a more conservative approach to leveraging debt.
Recent Debt Issuances and Credit Ratings
Inogen has not reported any recent debt issuances as of the latest financial statements. The company focuses on maintaining a manageable level of debt, which is reflected in its credit rating. As of the latest updates, the company has received ratings that suggest a stable outlook, reflecting confidence from credit rating agencies in its ability to manage its debt obligations.
Balancing Between Debt Financing and Equity Funding
Inogen has historically financed its operations through a combination of equity funding and revenue generated from sales and rentals. For the nine months ended September 30, 2024, the company raised approximately $0.8 million from stock option exercises and its employee stock purchase plan. This approach allows Inogen to retain flexibility in its capital structure while minimizing reliance on debt.
| Type of Financing | Amount (in millions) |
|---|---|
| Current Liabilities | $72.4 |
| Long-term Liabilities | $48.4 |
| Total Equity | $185.4 |
| Debt-to-Equity Ratio | 0.65 |
| Funds from Stock Option Exercises | $0.8 |
This table summarizes key financing metrics that illustrate how Inogen balances its growth through debt and equity financing strategies.
Assessing Inogen, Inc. (INGN) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
As of September 30, 2024, the current ratio stands at 2.66, calculated from total current assets of $192.6 million and total current liabilities of $72.4 million . The quick ratio, which excludes inventories from current assets, is approximately 2.48 when calculated with quick assets of $169.3 million .
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is $120.2 million, a decrease from $134.6 million at the end of 2023 . This trend indicates a reduction in the buffer available to meet short-term obligations, primarily influenced by fluctuations in current assets and liabilities. The total current assets decreased from $207.1 million to $192.6 million, while current liabilities remained relatively stable .
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, was $8.9 million, a significant shift from $(0.1 million) in the same period of 2023 . Investing activities saw a cash outflow of $25.5 million, compared to $63.4 million in 2023, reflecting a reduction in capital expenditures . Financing activities contributed $0.5 million during this period, down from $1.0 million in 2023 .
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Operating Activities | 8,932 | (86) | 9,018 |
| Investing Activities | (25,515) | (63,443) | 37,928 |
| Financing Activities | 525 | 974 | (449) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash and cash equivalents totaled $105.7 million, with additional marketable securities of $15.0 million . This liquidity position suggests a strong capability to cover immediate obligations. However, the decline in working capital and the increase in cash used for investing activities present potential concerns for future liquidity . The company’s ability to generate cash from operations will be critical in maintaining its liquidity position moving forward.
Is Inogen, Inc. (INGN) Overvalued or Undervalued?
Valuation Analysis
In evaluating the financial health of the company, key valuation metrics such as the price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios provide insights into whether the company is overvalued or undervalued.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a critical metric for assessing a company's valuation relative to its earnings. As of October 2024, the company's P/E ratio stands at –, indicating it is currently operating at a net loss, hence the absence of a meaningful P/E value.
Price-to-Book (P/B) Ratio
The P/B ratio offers insight into how the market values the company's equity compared to its book value. The current P/B ratio is 1.65, suggesting that investors are willing to pay $1.65 for every $1 of book value, indicating potential overvaluation based on book assets.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is another important valuation metric. The current EV/EBITDA ratio is – due to negative EBITDA, reflecting the company's ongoing operational challenges, which limits the applicability of this ratio in assessing valuation.
Stock Price Trends
Over the past 12 months, the stock price has shown significant volatility. The stock price has ranged from a low of $5.50 to a high of $9.75. As of October 2024, the stock is trading at $6.00, indicating a decline from its peak, which may reflect market sentiment regarding the company's financial recovery efforts.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, and thus the dividend yield stands at 0%. Given the ongoing net losses and focus on reinvestment into operations, a dividend payout ratio is not applicable at this time.
Analyst Consensus on Stock Valuation
According to recent analyst reports, the consensus rating for the stock is a Hold. Analysts cite concerns over the company's ability to return to profitability in the near term, given the ongoing operational losses and market conditions.
| Valuation Metric | Current Value |
|---|---|
| P/E Ratio | – |
| P/B Ratio | 1.65 |
| EV/EBITDA Ratio | – |
| 12-Month Low Stock Price | $5.50 |
| 12-Month High Stock Price | $9.75 |
| Current Stock Price | $6.00 |
| Dividend Yield | 0% |
| Analyst Consensus Rating | Hold |
Key Risks Facing Inogen, Inc. (INGN)
Key Risks Facing Inogen, Inc.
Inogen, Inc. faces a variety of internal and external risks that could impact its financial health. Below is a detailed breakdown of these risks:
Industry Competition
The market for portable oxygen concentrators is highly competitive, with numerous established players and new entrants. As of September 30, 2024, the company reported a significant increase in sales, selling approximately 119,100 oxygen systems, up from 96,400 in the previous year, representing a 23.5% increase. However, competition from other manufacturers could pressure margins and market share, particularly in the business-to-business segment.
Regulatory Changes
Changes in healthcare regulations and reimbursement policies can significantly affect revenue. The company has noted fluctuations in rental revenue, decreasing by 9.2% for the nine months ended September 30, 2024, primarily due to lower reimbursement rates. This trend may continue as Medicare and private payor policies evolve.
Market Conditions
Economic downturns or changes in healthcare funding can impact customer purchasing behavior. For instance, rental revenue decreased by $4.4 million for the nine months ended September 30, 2024. If market conditions worsen, demand for oxygen systems may decline, affecting overall sales.
Operational Risks
Operational risks include supply chain disruptions and the ability to scale production effectively. The company reported a 4.7% decrease in the cost of sales revenue due to lower premiums paid for raw materials, which may indicate a reliance on stable supply chains. Any disruption could impact production and lead to increased costs.
Financial Risks
Financial risks include liquidity concerns and the ability to raise capital. As of September 30, 2024, the company had cash and cash equivalents of $105.7 million and marketable securities of $15.0 million. However, future funding needs may arise, and if the company requires additional funds, it may not be able to obtain them on favorable terms.
Strategic Risks
The company is also exposed to strategic risks related to market acceptance of new products. Research and development expenses increased by 11.2% for the nine months ended September 30, 2024, indicating a focus on innovation. However, failure to successfully launch new products could hinder growth.
Mitigation Strategies
To address these risks, Inogen, Inc. has implemented several strategies:
- Strengthening relationships with healthcare providers to enhance market penetration.
- Investing in research and development to innovate and diversify product offerings.
- Monitoring regulatory changes closely to adapt business practices accordingly.
- Maintaining a healthy cash reserve to manage liquidity risks effectively.
| Risk Type | Current Impact | Mitigation Strategy |
|---|---|---|
| Industry Competition | Increased sales but pressure on margins | Enhance product differentiation and customer relationships |
| Regulatory Changes | Decreased rental revenue due to lower reimbursements | Regularly review and adapt to changing regulations |
| Market Conditions | Potential decline in demand | Diverse marketing strategies to maintain customer base |
| Operational Risks | Supply chain disruptions impacting production | Develop contingency plans and diversify suppliers |
| Financial Risks | Liquidity concerns affecting operational flexibility | Maintain cash reserves and explore funding options |
| Strategic Risks | Failure to innovate could hinder growth | Invest in R&D and monitor market trends |
Future Growth Prospects for Inogen, Inc. (INGN)
Future Growth Prospects for Inogen, Inc.
Product Innovations: The company has focused on enhancing its product offerings, particularly in oxygen concentrators. For the nine months ended September 30, 2024, sales revenue reached $212,449,000, a 10.5% increase from $192,203,000 during the same period in 2023. The total number of oxygen systems sold surged to approximately 119,100, marking a 23.5% increase from 96,400 units sold in the previous year.
Market Expansions: The company has made significant strides in both domestic and international markets. Domestic business-to-business sales amounted to $61,158,000, reflecting a 27.0% increase from $48,145,000 in 2023. International business-to-business sales saw an even larger growth, with revenues reaching $88,894,000, up 31.0% from $67,877,000.
Future Revenue Growth Projections: Total revenue for the nine months ended September 30, 2024, was $255,624,000, which is a 6.6% increase compared to $239,764,000 in the same period of 2023. The company aims to continue this upward trajectory through strategic market penetration and product innovation.
Strategic Initiatives and Partnerships: The company plans to enhance its rental business by investing in patient and physician awareness, expanding clinical evidence, and securing additional insurance contracts. This is essential as rental revenue decreased to $43,175,000 from $47,561,000, a 9.2% decline.
| Metric | 2024 | 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $255,624,000 | $239,764,000 | $15,860,000 | 6.6% |
| Sales Revenue | $212,449,000 | $192,203,000 | $20,246,000 | 10.5% |
| Rental Revenue | $43,175,000 | $47,561,000 | ($4,386,000) | -9.2% |
| Domestic B2B Sales | $61,158,000 | $48,145,000 | $13,013,000 | 27.0% |
| International B2B Sales | $88,894,000 | $67,877,000 | $21,017,000 | 31.0% |
Competitive Advantages: The company maintains a competitive edge through its focus on technology and customer service, which enhances patient experiences and drives demand. The gross margin on sales revenue improved to 47.2% for Q3 2024, up from 37.2% in Q3 2023, attributed to lower material costs and a shift towards business-to-business sales.
Research and Development: For the nine months ended September 30, 2024, research and development expenses were $15,712,000, an increase of 11.2% from $14,126,000 in 2023. This investment is crucial for ongoing product innovations and maintaining market relevance.
Overall, with a robust strategy focusing on market expansion, product innovation, and operational efficiencies, the company is well-positioned for future growth.
Inogen, Inc. (INGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Inogen, Inc. (INGN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Inogen, Inc. (INGN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Inogen, Inc. (INGN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.